Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.

Jacobs SA, Robidoux A, Abraham J, Pérez-Garcia JM, La Verde N, Orcutt JM, Cazzaniga ME, Piette F, Antolín S, Aguirre E, Cortes J, Llombart-Cussac A, Di Cosimo S, Kim RS, Feng H, Lipchik C, Lucas PC, Srinivasan A, Wang Y, Song N, Gavin PG, Balousek AD, Paik S, Allegra CJ, Wolmark N, Pogue-Geile KL.

Breast Cancer Res. 2020 Jan 22;22(1):9. doi: 10.1186/s13058-019-1240-y.

2.

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer.

Lopez-Bonet E, Buxó M, Cuyàs E, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Oliveras G, Meléndez C, Castillo L, Verdura S, Brunet J, Joven J, Garcia M, Saidani S, Martin-Castillo B, Menendez JA.

J Clin Med. 2019 Dec 11;8(12). pii: E2180. doi: 10.3390/jcm8122180.

3.

Establishment of a conditional Nomo1 mouse model by CRISPR/Cas9 technology.

García-Tuñón I, Vuelta E, Lozano L, Herrero M, Méndez L, Palomero-Hernandez J, Pérez-Caro M, Pérez-García J, González-Sarmiento R, Sánchez-Martín M.

Mol Biol Rep. 2020 Feb;47(2):1381-1391. doi: 10.1007/s11033-019-05214-7. Epub 2019 Dec 12.

PMID:
31833031
4.

Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients.

Cortés J, Ciruelos E, Pérez-García J, Albanell J, García-Estévez L, Ruiz-Borrego M, Espinosa R, Gallegos I, González S, Álvarez I, Llombart A.

Cancer Treat Rev. 2020 Feb;83:101944. doi: 10.1016/j.ctrv.2019.101944. Epub 2019 Nov 29. Review.

PMID:
31830538
5.

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.

Jacobs SA, Robidoux A, Abraham J, Pérez-Garcia JM, La Verde N, Orcutt JM, Cazzaniga ME, Piette F, Antolín S, Aguirre E, Cortes J, Llombart-Cussac A, Di Cosimo S, Kim RS, Feng H, Lipchik C, Lucas PC, Srinivasan A, Wang Y, Song N, Gavin PG, Balousek AD, Paik S, Allegra CJ, Wolmark N, Pogue-Geile KL.

Breast Cancer Res. 2019 Dec 3;21(1):133. doi: 10.1186/s13058-019-1196-y. Erratum in: Breast Cancer Res. 2020 Jan 22;22(1):9.

6.

Association of Polyps with Early-Onset Colorectal Cancer and Throughout Surveillance: Novel Clinical and Molecular Implications.

Perea García J, Arribas J, Cañete Á, García JL, Álvaro E, Tapial S, Narváez C, Vivas A, Brandáriz L, Hernández-Villafranca S, Rueda D, Rodríguez Y, Pérez-García J, Olmedillas-López S, García-Olmo D, Cavestro GM, Urioste M, Goel A, González-Sarmiento R.

Cancers (Basel). 2019 Nov 29;11(12). pii: E1900. doi: 10.3390/cancers11121900.

7.

Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases.

Sampayo-Cordero M, Miguel-Huguet B, Pardo-Mateos A, Malfettone A, Pérez-García J, Llombart-Cussac A, Cortés J, Moltó-Abad M, Muñoz-Delgado C, Pérez-Quintana M, Pérez-López J.

Orphanet J Rare Dis. 2019 Oct 21;14(1):230. doi: 10.1186/s13023-019-1202-6.

8.

Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.

Hui R, Pearson A, Cortes J, Campbell C, Poirot C, Azim HA Jr, Fumagalli D, Lambertini M, Daly F, Arahmani A, Perez-Garcia J, Aftimos P, Bedard PL, Xuereb L, Scheepers ED, Vicente M, Goulioti T, Loibl S, Loi S, Pierrat MJ, Turner NC, Andre F, Curigliano G.

Clin Cancer Res. 2020 Jan 15;26(2):354-363. doi: 10.1158/1078-0432.CCR-19-1164. Epub 2019 Oct 16.

PMID:
31619444
9.

Incidence and underreporting of leptospirosis comparing three diagnostic methods in the endemic region of Urabá, Colombia

Pérez-García J, Agudelo-Flórez P, Parra-Henao GJ, Ochoa JE, Arboleda M.

Biomedica. 2019 May 1;39(s1):150-162. doi: 10.7705/biomedica.v39i0.4577. English, Spanish.

10.

Window of Opportunity trials for biomarker discovery in breast cancer.

Arnedos M, Roulleaux Dugage M, Perez-Garcia J, Cortes J.

Curr Opin Oncol. 2019 Nov;31(6):486-492. doi: 10.1097/CCO.0000000000000583.

PMID:
31464762
11.

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.

Baird RD, van Rossum AGJ, Oliveira M, Beelen K, Gao M, Schrier M, Mandjes IAM, Garcia-Corbacho J, Vallier AL, Dougall G, van Werkhoven E, Linossi C, Kumar S, van Tinteren H, Callari M, Beddowes E, Perez-Garcia JM, Rosing H, Platte E, Nederlof P, Schot M, de Vries Schultink A, Bernards R, Saura C, Gallagher W, Cortès J, Caldas C, Linn SC.

Clin Cancer Res. 2019 Nov 15;25(22):6598-6605. doi: 10.1158/1078-0432.CCR-19-0508. Epub 2019 Aug 22.

PMID:
31439579
12.

Spatiotemporal variations of organochlorine pesticides in an apex predator: Influence of government regulations and farming practices.

Gómez-Ramírez P, Pérez-García JM, León-Ortega M, Martínez JE, Calvo JF, Sánchez-Zapata JA, Botella F, María-Mojica P, Martínez-López E, García-Fernández AJ.

Environ Res. 2019 Sep;176:108543. doi: 10.1016/j.envres.2019.108543. Epub 2019 Jun 20.

PMID:
31260915
13.

Scavenging in the Anthropocene: Human impact drives vertebrate scavenger species richness at a global scale.

Sebastián-González E, Barbosa JM, Pérez-García JM, Morales-Reyes Z, Botella F, Olea PP, Mateo-Tomás P, Moleón M, Hiraldo F, Arrondo E, Donázar JA, Cortés-Avizanda A, Selva N, Lambertucci SA, Bhattacharjee A, Brewer A, Anadón JD, Abernethy E, Rhodes OE Jr, Turner K, Beasley JC, DeVault TL, Ordiz A, Wikenros C, Zimmermann B, Wabakken P, Wilmers CC, Smith JA, Kendall CJ, Ogada D, Buechley ER, Frehner E, Allen ML, Wittmer HU, Butler JRA, du Toit JT, Read J, Wilson D, Jerina K, Krofel M, Kostecke R, Inger R, Samson A, Naves-Alegre L, Sánchez-Zapata JA.

Glob Chang Biol. 2019 Sep;25(9):3005-3017. doi: 10.1111/gcb.14708. Epub 2019 Jun 24.

PMID:
31127672
14.

The safety of eribulin for the treatment of metastatic breast cancer.

Perez-Garcia JM, Cortes J.

Expert Opin Drug Saf. 2019 May;18(5):347-355. doi: 10.1080/14740338.2019.1608946. Epub 2019 May 20. Review.

PMID:
31107111
15.

Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients.

Cuyàs E, Fernández-Arroyo S, Buxó M, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Verdura S, Brunet J, López-Bonet E, Garcia M, Saidani S, Joven J, Martin-Castillo B, Menendez JA.

Aging (Albany NY). 2019 May 9;11(9):2874-2888. doi: 10.18632/aging.101960.

16.

Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept.

Ciruelos E, Pérez-García JM, Gavilá J, Rodríguez A, de la Haba-Rodriguez J.

Clin Drug Investig. 2019 Jul;39(7):595-606. doi: 10.1007/s40261-019-00790-9. Review.

PMID:
31054086
17.

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin.

Cuyàs E, Buxó M, Ferri Iglesias MJ, Verdura S, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Joven J, Brunet J, López-Bonet E, Garcia M, Saidani S, Queralt Moles X, Martin-Castillo B, Menendez JA.

Front Oncol. 2019 Mar 28;9:193. doi: 10.3389/fonc.2019.00193. eCollection 2019.

18.

Diagnostic accuracy of ultrasound and fine-needle aspiration in the study of thyroid nodule and multinodular goitre.

Rabal Fueyo A, Vilanova Serra M, Lerma Puertas E, Montserrat Esplugas E, Pérez García JI, Mato Matute E, De Leiva Hidalgo A, Moral Duarte A.

Endocrinol Diabetes Metab. 2018 Jun 19;1(3):e00024. doi: 10.1002/edm2.24. eCollection 2018 Jul.

19.

Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.

Ortega V, Antón A, Garau I, Afonso N, Calvo L, Fernández Y, Martínez-García M, Blanco E, Zamora P, García M, Illarramendi JJ, Rodríguez Sánchez CA, Sampayo M, Aguirre E, Pérez-García JM, Cortés J, Llombart-Cussac A.

Clin Breast Cancer. 2019 Apr;19(2):105-112. doi: 10.1016/j.clbc.2018.12.012. Epub 2018 Dec 20.

PMID:
30679100
20.

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.

Gavilá J, Oliveira M, Pascual T, Perez-Garcia J, Gonzàlez X, Canes J, Paré L, Calvo I, Ciruelos E, Muñoz M, Virizuela JA, Ruiz I, Andrés R, Perelló A, Martínez J, Morales S, Marín-Aguilera M, Martínez D, Quero JC, Llombart-Cussac A, Prat A.

BMC Med. 2019 Jan 9;17(1):8. doi: 10.1186/s12916-018-1233-1. No abstract available.

21.

Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.

Pérez-Garcia J, Cortés J, Metzger Filho O.

Oncologist. 2019 Aug;24(8):1041-1047. doi: 10.1634/theoncologist.2018-0182. Epub 2018 Dec 21.

22.

A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study.

Martin-Castillo B, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Stradella A, Morilla I, Viñas G, Cortés J, Cuyàs E, Verdura S, Fernández-Ochoa Á, Fernández-Arroyo S, Segura-Carretero A, Joven J, Pérez E, Bosch N, Garcia M, López-Bonet E, Saidani S, Buxó M, Menendez JA.

Oncotarget. 2018 Nov 2;9(86):35687-35704. doi: 10.18632/oncotarget.26286. eCollection 2018 Nov 2.

23.

CXCR4 antagonists for treatment of breast cancer.

Cortés J, Holgado E, Perez-Garcia J.

Oncotarget. 2018 Sep 11;9(71):33442-33443. doi: 10.18632/oncotarget.26090. eCollection 2018 Sep 11. No abstract available.

24.

Drivers of daily movement patterns affecting an endangered vulture flight activity.

García-Jiménez R, Pérez-García JM, Margalida A.

BMC Ecol. 2018 Sep 29;18(1):39. doi: 10.1186/s12898-018-0195-7.

25.

Is there a role for immunotherapy in HER2-positive breast cancer?

Holgado E, Perez-Garcia J, Gion M, Cortes J.

NPJ Breast Cancer. 2018 Aug 15;4:21. doi: 10.1038/s41523-018-0072-8. eCollection 2018. Review.

26.

Digital PET/CT vs. analogue PET/CT in a parathyroid gland study with 18F-Fluorocholine.

López-Mora DA, Estorch M, Fuentes-Ocampo F, Pérez García JI, Moral A, Carrio I.

Rev Esp Med Nucl Imagen Mol. 2019 Mar - Apr;38(2):121-122. doi: 10.1016/j.remn.2018.06.003. Epub 2018 Jul 30. English, Spanish. No abstract available.

PMID:
30072302
27.

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.

Pernas S, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Perez-Garcia J, Wach A, Barker D, Fung S, Romagnoli B, Cortes J.

Lancet Oncol. 2018 Jun;19(6):812-824. doi: 10.1016/S1470-2045(18)30147-5. Epub 2018 Apr 26.

PMID:
29706375
28.

Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis.

Cortes J, Pérez-García J, Whiting S, Wan Y, Solem C, Tai MH, Margunato-Debay S, Ko A, Fandi A, Botteman M.

Clin Breast Cancer. 2018 Oct;18(5):e919-e926. doi: 10.1016/j.clbc.2018.03.014. Epub 2018 Mar 30.

29.

Pancreatic stent insertion after an unintentional guidewire cannulation of the pancreatic duct during ERCP.

García-Cano J, Viñuelas Chicano M, Del Moral Martínez M, Muñiz Muñoz M, Murillo Matamoros C, Suárez Matías M, Valiente González L, Martínez Pérez T, Martínez Fernández R, Gómez Ruiz CJ, Pérez García JI, Morillas Ariño J.

Rev Esp Enferm Dig. 2018 Jul;110(7):416-420. doi: 10.17235/reed.2018.5230/2017.

30.

Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer.

Cortes J, Perez-Garcia J, Levy C, Gómez Pardo P, Bourgeois H, Spazzapan S, Martínez-Jañez N, Chao TC, Espié M, Nabholtz JM, Gonzàlez Farré X, Beliakouski V, Román García J, Holgado E, Campone M.

Ann Oncol. 2018 Apr 1;29(4):881-887. doi: 10.1093/annonc/mdy051.

PMID:
29481630
31.

Wildfires as collateral effects of wildlife electrocution: An economic approach to the situation in Spain in recent years.

Guil F, Soria MÁ, Margalida A, Pérez-García JM.

Sci Total Environ. 2018 Jun 1;625:460-469. doi: 10.1016/j.scitotenv.2017.12.242. Epub 2017 Dec 29.

PMID:
29291560
32.

Breast cancer in 2017: Spurring science, marking progress, and influencing history.

Perez-Garcia J, Cortes J.

Nat Rev Clin Oncol. 2018 Feb;15(2):79-80. doi: 10.1038/nrclinonc.2017.191. Epub 2017 Dec 12. Review. No abstract available.

PMID:
29231194
33.

Targeting FGFR pathway in breast cancer.

Perez-Garcia J, Muñoz-Couselo E, Soberino J, Racca F, Cortes J.

Breast. 2018 Feb;37:126-133. doi: 10.1016/j.breast.2017.10.014. Epub 2017 Nov 20. Review.

PMID:
29156384
34.

The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies.

Cortés J, Im SA, Holgado E, Perez-Garcia JM, Schmid P, Chavez-MacGregor M.

Cancer Treat Rev. 2017 Dec;61:53-60. doi: 10.1016/j.ctrv.2017.09.011. Epub 2017 Oct 12. Review.

35.

Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice.

de Melo Gagliato D, Cortes J, Curigliano G, Loi S, Denkert C, Perez-Garcia J, Holgado E.

Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):527-537. doi: 10.1016/j.bbcan.2017.10.003. Epub 2017 Oct 20. Review.

PMID:
29061314
36.

Corrigendum to "Per- and polyfluoroalkyl substances in plasma and feathers of nestling birds of prey from Northern Norway" [Environ. Res. 158 (2017) 277-285].

Gómez-Ramírez P, Bustnes JO, Eulaers I, Herzke D, Johnsen TV, Lepoint G, Pérez-García JM, García-Fernández AJ, Jaspers VLB.

Environ Res. 2017 Nov;159:648-649. doi: 10.1016/j.envres.2017.09.008. Epub 2017 Sep 20. No abstract available.

PMID:
28941637
37.

NRAS-mutant melanoma: current challenges and future prospect.

Muñoz-Couselo E, Adelantado EZ, Ortiz C, García JS, Perez-Garcia J.

Onco Targets Ther. 2017 Aug 8;10:3941-3947. doi: 10.2147/OTT.S117121. eCollection 2017. Review.

38.

Per- and polyfluoroalkyl substances in plasma and feathers of nestling birds of prey from northern Norway.

Gómez-Ramírez P, Bustnes JO, Eulaers I, Herzke D, Johnsen TV, Lepoint G, Pérez-García JM, García-Fernández AJ, Jaspers VLB.

Environ Res. 2017 Oct;158:277-285. doi: 10.1016/j.envres.2017.06.019. Epub 2017 Jun 26. Erratum in: Environ Res. 2017 Nov;159:648-649.

PMID:
28662453
39.

Role of total tumour load of sentinel lymph node on survival in early breast cancer patients.

Peg V, Sansano I, Vieites B, Bernet L, Cano R, Córdoba A, Sancho M, Martín MD, Vilardell F, Cazorla A, Espinosa-Bravo M, Pérez-García JM, Cortés J, Rubio IT, Ramón Y Cajal S.

Breast. 2017 Jun;33:8-13. doi: 10.1016/j.breast.2017.02.011. Epub 2017 Feb 28.

PMID:
28254641
40.

Breast abscess along with pulmonary mass found in an immunocompetent patient.

Seseña-Del Olmo G, Serrano-Cazorla M, Pérez-García J, González IM.

Enferm Infecc Microbiol Clin. 2018 Jan;36(1):55-56. doi: 10.1016/j.eimc.2016.07.003. Epub 2016 Nov 18. English, Spanish. No abstract available.

PMID:
27876191
41.

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, Wolf J.

J Clin Oncol. 2017 Jan 10;35(2):157-165. Epub 2016 Nov 21. Erratum in: J Clin Oncol. 2017 Mar 10;35(8):926. J Clin Oncol. 2019 Feb 1;37(4):358.

42.

Spatial and temporal movements in Pyrenean bearded vultures (Gypaetus barbatus): Integrating movement ecology into conservation practice.

Margalida A, Pérez-García JM, Afonso I, Moreno-Opo R.

Sci Rep. 2016 Oct 25;6:35746. doi: 10.1038/srep35746.

43.

Point-of-care capillary HbA1c measurement in the emergency department: a useful tool to detect unrecognized and uncontrolled diabetes.

Gomez-Peralta F, Abreu C, Andreu-Urioste L, Antolí AC, Rico-Fontsaré C, Martín-Fernández D, Resina-Rufes R, Pérez-García JJ, Negrete-Muñoz Á, Muñoz-Álvarez D, Umpierrez GE.

Int J Emerg Med. 2016 Dec;9(1):7. doi: 10.1186/s12245-016-0107-6. Epub 2016 Feb 19.

44.

[Childhood leptospirosis in patients with febrile syndrome in the Region of Urabá, Colombia].

Pérez-García J, Arboleda M, Agudelo-Flórez P.

Rev Peru Med Exp Salud Publica. 2016 Oct-Dec;33(4):745-750. doi: 10.17843/rpmesp.2016.334.2561. Spanish.

45.

Recent advances in the treatment of melanoma with BRAF and MEK inhibitors.

Muñoz-Couselo E, García JS, Pérez-García JM, Cebrián VO, Castán JC.

Ann Transl Med. 2015 Sep;3(15):207. doi: 10.3978/j.issn.2305-5839.2015.05.13. Review.

46.

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.

De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L.

Oncotarget. 2015 Nov 10;6(35):37269-80. doi: 10.18632/oncotarget.5495.

47.

High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.

Nuciforo P, Thyparambil S, Aura C, Garrido-Castro A, Vilaro M, Peg V, Jimenez J, Vicario R, Cecchi F, Hoos W, Burrows J, Hembrough T, Ferreres JC, Perez-Garcia J, Arribas J, Cortes J, Scaltriti M.

Mol Oncol. 2016 Jan;10(1):138-147. doi: 10.1016/j.molonc.2015.09.002. Epub 2015 Sep 15.

48.

Genetic Signatures of Demographic Changes in an Avian Top Predator during the Last Century: Bottlenecks and Expansions of the Eurasian Eagle Owl in the Iberian Peninsula.

Graciá E, Ortego J, Godoy JA, Pérez-García JM, Blanco G, Delgado Mdel M, Penteriani V, Almodóvar I, Botella F, Sánchez-Zapata JA.

PLoS One. 2015 Jul 31;10(7):e0133954. doi: 10.1371/journal.pone.0133954. eCollection 2015.

49.

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.

Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, Baselga J.

Sci Transl Med. 2015 Apr 15;7(283):283ra51. doi: 10.1126/scitranslmed.aaa4442. Erratum in: Sci Transl Med. 2018 Oct 24;10(464):.

50.

Acral injury as first manifestation of a metastatic adenocarcinoma of the colon.

Valiente-González L, Martínez-Pérez T, Jiménez-Martínez Y, Martínez-Fernández R, Viñuelas-Chicano M, Gómez-Ruiz CJ, Pérez-García JI, Morillas-Ariño J, Pérez-Vigara G, García-Cano-Lizcano J, Pérez-Sola Á.

Rev Esp Enferm Dig. 2015 Mar;107(3):171-2. No abstract available.

Supplemental Content

Loading ...
Support Center